Invention Grant
- Patent Title: 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof
-
Application No.: US16204730Application Date: 2018-11-29
-
Publication No.: US10683274B2Publication Date: 2020-06-16
- Inventor: Toshihiko Sone , Wataru Hirose , Naoaki Shimada , Chiang Li , Wei Li , David Leggett
- Applicant: Boston Biomedical, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Boston Biomedical, Inc.
- Current Assignee: Boston Biomedical, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Schwegman Lundberg & Woessner, P.A.
- Main IPC: C07D307/92
- IPC: C07D307/92 ; A61K31/343 ; A61K31/443 ; A61K31/497 ; C07D405/04 ; C07D405/12 ; C07D413/06
![3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof](/abs-image/US/2020/06/16/US10683274B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.
Public/Granted literature
- US20190241535A1 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Public/Granted day:2019-08-08
Information query